MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα

Figure 3

miR-137-3p agomir reduces hepatic oxidative stress and inflammation in HFD mice. (a) Mice were fed with a HFD for 24 weeks to establish NAFLD and were also intraperitoneally injected with the miR-137-3p agomir or agomir control (100 mg/kg weekly) at the last 6 consecutive weeks. Relative hepatic ROS level determined by DCFH-DA probe (). (b) Relative H₂O₂ level in the liver (). (c) MDA generation in the liver (). (d) NRF2 protein expression determined by western blot (). (e) GSH level in the liver (). (f) Total SOD and CAT activity in the liver (). (g) p65 phosphorylation determined by western blot (). (h, i) Hepatic IL-1β, IL-6, MCP-1, TNF-α, and IL-10 levels determined by the commercial ELISA kits (). Data were expressed as the , and was considered significant.